Practice of Fluid Therapy in Critically Ill Invasively Ventilated Patients
Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Jul 20, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how doctors use fluid and vasopressor therapy in critically ill patients who are on invasive ventilation, which means they need a machine to help them breathe. The researchers want to understand the current practices worldwide regarding these treatments and see how they relate to patient outcomes, such as how long patients stay on the ventilator, how long they are in the hospital, and their overall survival rates.
To participate in this study, patients must be at least 16 years old, admitted to an intensive care unit, and receiving invasive ventilation for more than 24 hours. The research team will closely monitor the treatments given and the resulting health outcomes. This study is currently recruiting participants and aims to gather valuable information that could improve care for critically ill patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Admitted to a participating intensive care unit;
- • Receiving invasive ventilation; and
- • Duration of ventilation \> 24 hours.
- Exclusion Criteria:
- • Age \< 16 years;
- • Patients transferred under invasive ventilation from another intensive care unit.
About Academisch Medisch Centrum Universiteit Van Amsterdam (Amc Uva)
The Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is a leading academic medical center in the Netherlands, dedicated to advancing healthcare through innovative research, education, and patient care. Affiliated with the University of Amsterdam, AMC-UvA integrates clinical practice with cutting-edge biomedical research, fostering a multidisciplinary approach to medical challenges. The institution actively engages in clinical trials to enhance treatment options and improve patient outcomes, while promoting collaboration among healthcare professionals, researchers, and academic institutions globally. With a commitment to excellence and a focus on translational medicine, AMC-UvA plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam, Noord Holland, Netherlands
Patients applied
Trial Officials
Pieter R. Tuinman, MD
Principal Investigator
Amsterdam UMC, location VUmc
Frederique Paulus, Professor
Principal Investigator
Amsterdam UMC, location AMC
Marcus J. Schultz, Professor
Principal Investigator
Mahidol Oxford Tropical Medicine Research Unit
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported